-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $70

Benzinga·06/01/2026 18:06:40
Listen to the news
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $71 to $70.